Table 4 Reported outcomes of recent cervical stereotactic ablative body radiotherapy boost studies
| Authors | Study type | Number of patients | Median follow-up (months) | Pelvic RT total dose (Gy) | Pelvic RT dose per fractionation (Gy) | Boost total dose (Gy) | Boost dose per fractionation (Gy) | Local control | Overall survival | Progression-free survival |
Late toxicity (Grade 3 or worse) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Haas et al. [12] | Retrospective | 6 | 14 | 50.4–61.2 | 1.8 | 19.5–20 | 4–6.5 | 100% (Overall) | 100% (Overall) | 100% (Overall) | 0% (Overall) |
| Marnitz et al. [13] | Retrospective | 11 | 6 | 50.4 | 1.8 | 30 | 6 | 100% (Overall) | 100% (Overall) | 100% (Overall) | 0% (Overall) |
| Hsieh et al. [14] | Retrospective | 9 | NR | 50–50.4 | 1.8–2 | 16–27 | 2–4.5 | 77.8% (3-year, LRC) | 46.9% (3-year) |
25.9% (3-year) | 0% (Overall) |
| Ito et al. [15] | Prospective phase I | 6 | 17 | 45 | 1.8 | 21–22.5 | 7–7.5 | 100% (Overall) | 100% (Overall) | 83.3% (Overall) | 0% (Overall) |
| Albuquerque et al. [16] | Prospective phase II | 15 | 19 | 45 | 1.8 | 28 | 7 | 70.1% (2-year) | 53.3% (2-year) |
46.7% (2-year) |
26.7% (2-year) |
| Dalwadi et al. [17] | Retrospective | 25 | 25 | 45–50.4 | 1.8 | 12–30 | 4–7 | 95.5% (2-year, LRC) | 95.5% (2-year) | NR | 4.0% (Overall) |
| Current study | Retrospective | 25 | 34.2 | 44–50.4 | 1.8–2 | 20–33 | 4–5.5 | 80.9% (3-year) | 77.1% (3-year) |
58.5% (3-year) | 20.0% (Overall) |